InterPrEP (II): internet-based pre-exposure prophylaxis (PrEP) with generic tenofovir DF/emtricitabine (TDF/FTC) in London: analysis of safety and outcomes

被引：0
|
作者：
Aloysius, I. [1 ]
Zdravkov, J. [1 ]
Whitlock, G. [1 ]
Alldis, J. [1 ]
Nwokolo, N. [1 ]
Aylward, A. [2 ]
Arvind, A. [2 ]
Wang, X. [3 ]
Day-Weber, I. [3 ]
McClure, M. [3 ]
Boffito, M. [3 ]
Smith, R. [4 ]
Houghton-Price, V. [4 ]
Hill, A. [5 ]
机构：
[1] Chelsea & Westminster Hosp, London, England
[2] Imperial Coll Sch Med, London, England
[3] Imperial Coll, London, England
[4] Metavirol Ltd, London, England
[5] St Stephens AIDS Trust, London, England
来源：
HIV MEDICINE | 2017年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
P32
引用
收藏
页码：25 / 25
页数：1
相关论文
共 19 条
  • [1] InterPrEP: internet-based pre-exposure prophylaxis (PrEP) with generic tenofovir DF/emtricitabine (TDF/FTC) in London -analysis of pharmacokinetics, safety and outcomes
    Wang, Xinzhu
    Nwokolo, Nneka
    Korologou-Linden, Roxanna
    Hill, Andrew
    Whitlock, Gary
    Day-Weber, Isaac
    McClure, Myra
    Boffito, Marta
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [2] InterPrEP. Internet-based pre-exposure prophylaxis with generic tenofovir DF/emtricitabine in London: an analysis of outcomes in 641 patients
    Aloysius, Isaac
    Savage, Anna
    Zdravkov, Jey
    Korologou-Linden, Roxanna
    Hill, Andrew
    Smith, Rachel
    Houghton-Price, Vicky
    Boffito, Marta
    Nwokolo, Nneka
    JOURNAL OF VIRUS ERADICATION, 2017, 3 (04) : 218 - 222
  • [3] InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes
    Wang, X.
    Nwokolo, N.
    Korologou-Linden, R.
    Hill, A.
    Whitlock, G.
    Day-Weber, I.
    McClure, M. O.
    Boffito, M.
    HIV MEDICINE, 2018, 19 (01) : 1 - 6
  • [4] of emtricitabine/tenofovir (FTC/TDF) for HIV pre-exposure prophylaxis in the United States by gender (2013-1Q2016)
    Bush, Staci
    Rawlings, Keith
    Magnuson, David
    Martin, Patty
    Lugo-Torres, Olga
    Mera-Giler, Robertino
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [5] Bone changes in young men ages 18-22 enrolled in a pre-exposure prophylaxis (PrEP) safety and demonstration study using tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)
    Mulligan, K.
    Rutledge, B.
    Kapogiannis, B. G.
    Siberry, G. K.
    Anderson, P. L.
    Landowitz, R. J.
    Rudy, B.
    Liu, N.
    Havens, P. L.
    Wilson, C. M.
    Hosek, S.
    ANTIVIRAL THERAPY, 2015, 20 : A21 - A22
  • [6] The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B
    Solomon, Marc M.
    Schechter, Mauro
    Liu, Albert Y.
    McManhan, Vanessa M.
    Guanira, Juan V.
    Hance, Robert J.
    Chariyalertsak, Suwat
    Mayer, Kenneth H.
    Grant, Robert M.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 71 (03) : 281 - 286
  • [7] Quantification of tenofovir disoproxil fumarate and emtricitabine in generic pre-exposure prophylaxis tablets obtained from the internet
    Wang, Xinzhu
    Nutland, Will
    Brady, Michael
    Green, Ian
    Boffito, Marta
    McClure, Myra
    INTERNATIONAL JOURNAL OF STD & AIDS, 2019, 30 (08) : 765 - 768
  • [8] Longer term safety of emtricitabine/tenofovir alafenamide (F/TAF) and emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP): DISCOVER trial week 96 results
    Ogbuagu, O.
    Podzamczer, D.
    Salazar, L.
    Henry, K.
    Asmuth, D.
    Wohl, D.
    Gilson, R.
    Shao, Y.
    Ebrahimi, R.
    Carter, C.
    Das, M.
    McCallister, S.
    Brunetta, J.
    Kronborg, G.
    Reeves, I.
    Spinner, C.
    HIV MEDICINE, 2020, 21 : 12 - 12
  • [9] ESTABLISHMENT OF A MONITORING SERVICE FOR MEN WHO HAVE SEX WITH MEN (MSM) TAKING GENERIC CO-FORMULATED TENOFOVIR DISOPROXIL FUMARATE (TDF)/EMTRICITABINE (FTC) AS PRE-EXPOSURE PROPHYLAXIS (PREP) AGAINST HIV INFECTION
    Nwokolo, Nneka
    Wang, Xinzhu
    Boffito, Marta
    McClure, Myra
    Suchak, Tara
    Whitlock, Gary
    SEXUALLY TRANSMITTED INFECTIONS, 2016, 92 : A6 - A6
  • [10] DISCOVER in Europe: a sub-analysis of the phase 3 randomized, controlled trial of daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP)
    Post, F.
    Spinner, C.
    Coll, P.
    Hawkins, T.
    Anderson, J.
    Zhong, L.
    McCallister, S.
    HIV MEDICINE, 2019, 20 : 243 - 244
12